Merck's MK-944A Phase II on hold

MRK put Phase II trials of MK-944A on hold after seeing renal toxicity in rats. MK-944A is a twice daily capsule of a new protease inhibitor plus MRK's Crixivan indinavir. Kidney problems were not see...